<DOC>
	<DOC>NCT00618124</DOC>
	<brief_summary>This study assesses the maximum tolerated dose, overall safety and antitumor activity of SU011248 in combination with capecitabine in patients with advanced solid tumors</brief_summary>
	<brief_title>A Study To Find The Best Doses Of SU011248 (Sunitinib) And Capecitabine When These Drugs Are Administered Together</brief_title>
	<detailed_description />
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<criteria>Patients with diagnosis of a solid cancer which is not responsive to standard therapy or for which no standard therapy exists Patient has good performance status (ECOG 0 or 1) Prior treatment with either SU011248 or capecitabine. Hypertension that cannot be controlled by medications</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>solid tumor malignancy, SU011248, sunitinib, capecitabine, Phase 1</keyword>
</DOC>